IMP: BOD resolution dated March 17, 2022

The Board resolution dated March 17, 2022, the Board of Directors of Imexpharm Corporation approved the following issues:

1. Approved the business plan in 2022:

Unit: billion dongs     

2. Approving the handling of bad debts according to the Debt Settlement Minutes dated December 16, 2021 with total amount of VND 281,771,286.
3. Aproving the credit limit in 2022.
4. Approving the divestment at Mephydica.
5. Approving the contents of General Meeting of Shareholders in 2022.

HOSE

>   KBC: Report on Outstanding Voting Shares (22/03/2022)

>   HSL: BOD resolution dated March 17, 2022 (22/03/2022)

>   GEX: Notice of adjustment of foreign ownership limit (22/03/2022)

>   KBC: Report on selling treasury shares (22/03/2022)

>   DRC: BOD resolution dated March 18, 2022 (22/03/2022)

>   CVIC2110: The record date for the list of holders (22/03/2022)

>   CTPB2101: The record date for the list of holders (22/03/2022)

>   CMWG2104: The record date for rights exercise due to maturity (22/03/2022)

>   VRE.KIS.M.CA.T.14: Report on the result of covered warrant distribution (22/03/2022)

>   VPB.KIS.M.CA.T.04: Report on the result of covered warrant distribution (21/03/2022)